|
Fig. 6
spry4 expression in tissue‐specific and global FGF signaling–perturbed embryos at 36 hpf. A,B: Transgenic embryos were treated with 4‐OHT at shield stage and heatshock‐treated at 11 ss. Wild‐type embryos were treated with SU5402 either continuously or for a 4‐hr pulse. C–E: spry4 expression was completely absent in embryos continuously treated with SU5402, and reduced or absent in fin buds of transgenic (drl‐based LPM priming or ubi‐based ubiquitous priming) or pulse‐treated embryos; lateral and dorsal views, anterior to the left; asterisks indicate loss of pectoral fin expression. F: Quantification of spry4 expression in embryos subjected to embryo‐wide or tissue‐specific signaling perturbations. Number “n” indicates number of individual embryos analyzed for each condition.